EC Number | Application | Comment | Organism |
---|---|---|---|
2.4.2.38 | medicine | xylose residues within the capsule polysaccharide are important for normal host-pathogen interaction, loss of CXT1p attenuates virulence | Cryptococcus neoformans |
2.4.2.38 | medicine | loss of XT1 leads to attenuation of virulence | Cryptococcus neoformans |
EC Number | Cloned (Comment) | Organism |
---|---|---|
2.4.2.38 | 5-kb PCR product cloned into the TOPO pCR2.1 vector and maintained in Escherichia coli DH5alpha | Cryptococcus neoformans |
2.4.2.38 | amplification of the gene with flanking regions (1.3 kb upstream of the start codon, 1 kb downstream of the gene) from serotype D (strain JEC21) genomic DNA for cloning in pCR2.1TOPO, generation of replacement cassettes for replacing endogenous CXT1p: (i) nourseothricin acetyltransferase resistance gene flanked by the CXT1p flanking regions, transformed as linear DNA in CAP67 strain, (ii) cxt1 gene lacking 3 two-thirds of the encoding sequence flanked by its flanking regions, transformed as linear DNA in JEC21 strain | Cryptococcus neoformans |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.4.2.38 | UDP-D-xylose + galactoxylomannan | Cryptococcus neoformans | - |
UDP + [beta-D-xylose-(1,2)]-galactoxylomannan | JEC21/cxt1delta and CAP67/cxt1delta lacking CXT1p: almost complete loss of beta-xylose residues (1,2)-linked to mannose, unchanged amounts of beta-xylose (1,3)-linked to galactose | ? | |
2.4.2.38 | UDP-D-xylose + glucuronoxylomannan | Cryptococcus neoformans | - |
UDP + [beta-D-xylose-(1,2)]-glucuronoxylomannan | JEC21/cxt1delta and CAP67/cxt1delta lacking CXT1p: 30% decrease in amount of xylose, 39% decrease in O-2 xylose-substituted mannose, 31.5% increase in O-2-unsubstituted mannose, loss of 1/3 of beta-(1,2)-linked xylose, revealed by NMR analyses | ? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.4.2.38 | Cryptococcus neoformans | - |
wild-type strain JEC20 (serotype D MAT a), wild-type strain JEC21 (serotype D MAT alpha), mutant strain CAP67 (serotype D MAT alpha cap59), mutant strain JEC21/cxt1delta (serotype D, isogenic MAT alpha, encapsulated and nourseothricin-resistant, lacking CXT1p), mutant strain CAP67/cxt1delta (serotype D, isogenic MAT alpha, acapsulated and nourseothricin-resistant, lacking CXT1p) | - |
2.4.2.38 | Cryptococcus neoformans | Q5K8R6 | strains JEC20, JEC21 and CAP67 | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.4.2.38 | additional information | lack of CXT1p in membranes from JEC21/cxt1delta and CAP67/cxt1delta leads to dramatic reduction in D-xylose-beta-(1,2)-D-mannose-alpha-(1,3)-D-mannose synthesising activity in presence of exogenously added substrate | Cryptococcus neoformans | ? | - |
? | |
2.4.2.38 | UDP-D-xylose + D-mannosyl-alpha-(1,3)-D-mannose | membranes, radiolabelled UDP-xylose, alpha-(1,3)-mannobiose (resembles backbone or dimannose moiety of natural substrates) | Cryptococcus neoformans | UDP + D-xylosyl-beta-(1,2)-D-mannosyl-alpha-(1,3)-D-mannose | product: trisaccharide with xylose moiety linked to reducing mannose of alpha-(1,3)-mannobiose, radiolabel detection by scintillation counting or thin layer chromatography and autoradiography, product purification for NMR and glycosyl linkage analyses | ? | |
2.4.2.38 | UDP-D-xylose + galactoxylomannan | - |
Cryptococcus neoformans | UDP + [beta-D-xylose-(1,2)]-galactoxylomannan | JEC21/cxt1delta and CAP67/cxt1delta lacking CXT1p: almost complete loss of beta-xylose residues (1,2)-linked to mannose, unchanged amounts of beta-xylose (1,3)-linked to galactose | ? | |
2.4.2.38 | UDP-D-xylose + glucuronoxylomannan | - |
Cryptococcus neoformans | UDP + [beta-D-xylose-(1,2)]-glucuronoxylomannan | JEC21/cxt1delta and CAP67/cxt1delta lacking CXT1p: 30% decrease in amount of xylose, 39% decrease in O-2 xylose-substituted mannose, 31.5% increase in O-2-unsubstituted mannose, loss of 1/3 of beta-(1,2)-linked xylose, revealed by NMR analyses | ? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.4.2.38 | beta-1,2-xylosyltransferase | - |
Cryptococcus neoformans |
2.4.2.38 | beta1,2-xylosyltransferase | - |
Cryptococcus neoformans |
2.4.2.38 | Cryptococcal xylosyltransferase | - |
Cryptococcus neoformans |
2.4.2.38 | Cxt1p | - |
Cryptococcus neoformans |
2.4.2.38 | XT1 | - |
Cryptococcus neoformans |
2.4.2.38 | Xt1p | - |
Cryptococcus neoformans |
2.4.2.38 | xylosyltransferase I | - |
Cryptococcus neoformans |
EC Number | General Information | Comment | Organism |
---|---|---|---|
2.4.2.38 | malfunction | loss of XT1 does not affect in vitro growth of mutant cells or general morphology of their capsules. The two main capsule polysaccharides, glucuronoxylomannan and galactoxylomannan, both are missing beta1,2-xylose residues. Deletion of XT1 leads to attenuation of cryptococcal growth in a mouse model of infection | Cryptococcus neoformans |
2.4.2.38 | physiological function | Xt1p has a defined role in capsule biosynthesis | Cryptococcus neoformans |